Roche gets EU approval for breast cancer drug Perjeta
ZURICH (Reuters) - Roche said on Tuesday it clinched European approval for its breast cancer drug Perjeta, fuelling the company's hopes that the drug will become the standard of care for an aggressive, incurable form of the disease. Roche aims to combine Perjeta with its older drug Herceptin, the company's second-biggest seller, for women with a form of cancer known as HER2-positive, which makes up about a quarter of all breast cancers and has no cure. U.S. health regulators approved the drug last June and Perjeta won initial backing from European authorities in December. ...
Source: news.yahoo.com
No comments:
Post a Comment